Navigation Links
Trodusquemine in Medical News

Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)

PLYMOUTH MEETING, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced the formation of its Trodusquemine Scientific Advisory Board (the "SAB"), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance ...

Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust

...tinued listing, which requires a minimum bid price for the Company's common stock of $1.00. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Announces Results of Special Meeting of Stockholders

...ove a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution). About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors

...able before making any voting or investment decision with respect to the Plan of Dissolution. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Implements Cash Conservation Plan

...order to maintain the ability to pursue business development strategies for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Gen...ely $8.1 million. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...

Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph

...o its Form 10-K which was filed on March 3, 2009 with the Securities and Exchange Commission. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera Corporation Announces 2008 Financial Results

...rease in clinical and third-party contract research expenses related to the trodusquemine (MSI-1436) program for the treatment of type 2 diabetes and obesity and an ...mber 31, 2008. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...

Genaera to Present at BIO CEO & Investor Conference

...he treatment of type 2 diabetes and obesity, on Tuesday, February 10, 2009 at 2:15 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference

... This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6 About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera to Present at Therapeutic Area Partnerships 2008

...6 for the treatment of type 2 diabetes and obesity on Tuesday, November 4, 2008 at 4:20 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...
Trodusquemine in Medical Technology

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

-Cohort 1 Data Promising for Type 2 Diabetes- PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Ge...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted - PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the tre...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of ...

Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit

PLYMOUTH MEETING, Pa., July 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced interim Phase 1 safety and pharmacokinetic (PK) data and new preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesit...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, du...

Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Sci...

Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia

New data supports recent IND and forms foundation for upcoming clinical programs PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), G...

Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)

- Second filing provides opportunity for additional indications and increased potential market - PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that the investigational new drug (IND) application submitted to...

Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)

Study in Overweight and Obese Type 2 Diabetics to Assess Safety and Pharmacokinetics in addition to Specialized Secondary Endpoints PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-...
Trodusquemine in Biological Technology

Genaera Receives Non-Compliance Notice from Nasdaq

...Company intends to file a certificate of dissolution and delist its common stock from Nasdaq. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera to Present at BIO-Europe 2008

...ientific Officer, will present a company overview on Tuesday, November 18, 2008 at 11:00 a.m. CET. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is...

Genaera Corporation Announces Second Quarter Financial Results

...ases in research and clinical costs related to the trodusquemine (MSI-1436) program for the treatment of obesity an...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ...

Genaera Corporation Elects Paul K. Wotton to Board of Directors

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation to Present at BIO Business Forum

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation Announces First Quarter Financial Results

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation Announces 2007 Financial Results

...uring, research and personnel costs related to the trodusquemine (MSI-1436) program for the treatment of type 2 dia...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ...

Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference

...focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. ...

Genaera Corporation Announces Third Quarter Financial Results

...emain on track with plan. Positive interim Phase 1 trodusquemine data announced in the quarter is another example o...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...

Genaera to Present at Biotech 2007 and BIO InvestorForum

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...
Other Tags
(Date:7/29/2014)... 29, 2014 The One Minute Herpes Cure ... Freeman, an herbal medicine specialist. Alison Freeman wanted to show ... , People interested in finding out more about this ... download it, as it is currently available in online format. ... natural remedies and herbal medicine tips that can help them ...
(Date:7/29/2014)... July 29, 2014 The Natural Multiple ... the inside story to Gary M. Levin’s cure program. ... cure method for this serious disorder. Levin says that ... conditions that can be found in patients. , ... surgeon. For many years, Levin has worked with patients ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica in 8 ... of naturally overcoming sciatica, in less than 7 days. ... sufferers that the cure is simple to achieve, when ... method is described as very fast, as it promises ... minutes per day treatment plan. , Read more ...
(Date:7/29/2014)... Parker Waichman LLP, a national law ... by defective drugs and medical devices, reports that a ... Canada who allege that they were never warned about ... low testosterone injection Delatestryl (Court File No. 3704CP/14). The ... Ontario Superior Court of Justice. , “Testosterone lawsuits have ...
(Date:7/29/2014)... Denver, Colorado (PRWEB) July 29, 2014 Daily ... is a powerful and holistic system that will teach users ... been tried by thousands of people, from all over the ... of the symptoms of this disorder in as quickly as ... will be gone faster than imagined. , The Fibroids ...
Breaking Medicine News(10 mins):Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System 2
(Date:7/29/2014)... In this fascinating journey to the edge of science, ... new book The Beginning and the End: Does our ... it cyclic? Are we alone in the universe? What ... cosmic evolution? Grounded in science and committed to philosophical ... rise of intelligent life is not an accident, but ...
(Date:7/29/2014)... 29, 2014  When it comes to technology, healthcare is usually ... the last. However, when it comes to wearables, healthcare is trying ... for the Internet of Things and its wearable cousins is less ... the healthcare industry, whether it,s in the hospital for a major ... With that in mind, InformationWeek editor Rodney Brown ...
(Date:7/29/2014)... genetics company, has received from the National Institutes ... a two-year project to support the further development ... genetic discovery. , Specifically, the grant supports ... web-based surveys to improve the company,s ability to ... survey tools to support the collection of a ...
Breaking Biology News(10 mins):Book: 'The Beginning and the End' 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
Other Contents